Prostate-specific antigen is found in the prostate in two forms, one with a low (30 000) and one with a high (100000) relative molecular mass. The latter has recently been found to be a complex of prostatespecific antigen with aj-antichymotrypsin.
Introduction
The determination of serum prostate-specific antigen (l, 2) has been shown to be a better diagnostic indicator than tartrate-inhibited or prostate-specific acid phosphatase (3, 4) . Although prostate-specific antigen has a better diagnostic sensitivity and specificity than its predecessors, it is unsuitable for screening for prostatic cancer (7) , because many patients with benign disease of the prostate show elevated values in assays using this antigen (5, 6) .
Since prostate-specific antigen is coniplexed with Oiantichymotrypsin (8) , most probably to neutralise the protease activity of prostate-specific antigen (9) (analogous to the formation of elastase-oCi-antitrypsin complexes in serum (10) ), an assay was established to measure prostate-specific antigen-aj-antichymotrypsin complexes in serum.
The assay was compared with a classical radioimmunoassay for prostate-specific antigen (11), s well s with an irnmunoluminometric assay for serum oCiantichymotrypsin. The latter assay was used to test for the possible influence of high native oti-antichymotrypsin concentrations in falsifying the results of the prostate-specific antigen-arantichymotrypsin complex assays.
Materials and Methods
Antibodies to prostate-specific antigen were obtained from DAKO (Hamburg, Germany).
Antibodies to arantichymotrypsin were purchased from DAKO and Atlantic Antibodies (Baxter, Munich, Germany).
Polystyrene balls for the solid ph se (6.4 mm diameter) were ordered from Spherotech Kugeln (Fulda, Germany).
Streptavidin was purchased from Calbiochem-Behring (Frankfurt a. M., Germany), and amidocaproylbiotin-N-hydroxysuccinimide ester from Sigma (Deisenhofen, Germany).
The luminescent label, 9-(4-succinimidobutyl-N-ethyl) aminobenzo (0 phthalazine-1,4 (2H, 3H) dione (ABEN-H), was synthesised according to Schroeder et al. (12) and was coupled to antibodies after synthesis of its N-hydroxysuccinimide ester (13) . The radioimmunoassay kit used for comparison was the prostate-specific antigen (ProsChek RIA) from Yang Laboratories (1BL, Hamburg, Germany). Standards for the prostate-specific antigen-oci-antichymotrypsin complex assay were calibrated in terms of the prostate-specific antigen content in both the Yang RIA and Hybritech prostate-specific antigen-immunoradiometric assay.
The ai-antichymotrypsin Standard serum was obtained from Behringwerke (Marburg a. d. L., Germany), (Code No. OUCL 06/07).
Radioactivity was counted in an automatic gamma spectrometer (LKB 1277 Gammamaster) with on-line PC (Pharmacia, Freiburg, Germany). Liiminescence was measured in a 250-sample semiautomatic luminometer LB 952-16T -(EG & G Berthold, Wildbad, Germany).
The assay schemes for prostate-specific antigen, a r antichymotrypsin and prostate-specific antigen-ai-antichymotrypsin complex are shown in tables la-Ic.
For establishinent of reference ranges and to check for specificity ("paraneoplastic-prostate-specific antigen" production in other tumours), samples were obtained from healthy volunteers and patients attending the urology clinic, s well s patients with renal insufficiency, lung cancer and other benign, nonprostatic diseases. Data from 270 patients were studied during the evalu tion period.
Statistics
Statistics were carried out using non-parametric tests. The Mann-Whitney U-Test was used for independent variables, the Wilcoxon signed rank test for paired data and the Spearman rank test for regression analysis. The data distribution was checked with the Kolmogorov Smirnofftest at the level α = 0.05. 
Establishment of reference ranges
The prostate-specific antigen radioimmunoassay was carried out according to the manufacturer's instructions using the overnight incubation at room temperature. The reference ranges (95% confidence limits) established in 82 hospitalised male patients with non-prostate diseases and without bacterial infections were 0.13-4.63 μg/l (median 1.60) for prostate-specific antigen, and 0.08-1.78 μg/l (median 0.60) for prostate-specific antigen-ai-antichymotrypsin complex.
The reference ranges (95% confidence limits) were established for a r antichymotrypsin in 80 patients, male and female, attending outpatient clinics, who were free from bacterial or viral infection and malignant disease. The 95% confidence limits for a r antichymotrypsin were 0.27-0.61 g/l (median 0.38). There was no difference between a r antichymotrypsin in males and females (p > 0.75).
There was a positive correlation between serum prostate-specific antigen and prostate-specific antigen-oc r antichymotrypsin complex in the reference group (r = 0.63, p < 0.01, slope 0.25, intercept 0.27) and no difference between serum and plasma values. There was a close correlation between prostate-specific antigen and prostate-specific antigen-a r antichymotrypsin complex over the whole concentration r nge (0-410 μg/l a r antichymotrypsin; 0-270 μg/l prostate-specific antigen-ocrantichymotrypsin complex) (r = 0.85, p < 0.01, slope 0.57, intercept -0.92).
The correlation between a r antichymotrypsin in serum and plasma was excellent (r = 1.00, slope = 0.998, intercept = 0.03 g/l), so that plasma or serum samples could be used for all three assays. In contrast to other studies (14) , prostate-specific antigen was present at detectable levels in serum from females. This is not surprising, since prostate-specific antigen has been detected histochemically in urethral glands from both sexes (15) .
Assay precision data Table 2 shows the basic quality control data for all 3 assays. The intra-assay precision was represented by a compound precision profile, the inter-assay precision by conventional means, i. e. from the measurement of control sera in consecutive assays.
Specificity of the prostate-specific antigen-(Xi-antichymotrypsin complex assay Levels of up to 200 μg/l purified prostate-specific antigen measured in the prostate-specific antigen-aiantichymotrypsin complex assay gave values less than the first Standard (0.15 μg/l) 9 showing the assay to be specific for prostate-specific antigen-a t -antichymotrypsin complexes.
Neither prostate-specific antigen-ot! antitrypsin nor prostate-specific antigen-a 2 macroglobulin complexes were detectable in serum or plasma when measured with sandwich assays, showing that prostate-specific antigen forms specific complexes with oti-antichymotrypsin (8) but most probably not with other antiproteases. Attempts at complexing oti-antichymotrypsin, in the form of fresh plasma, with purified prostatespecific antigen (M r 30000) did not result in complexes being formed in vitro.
This is in contrast to purified neutrophil elastase, which readily forms complexes with tti-antiproteinase and a 2 -macroglobulin present in fresh plasma.
Experimental groups

Sex-related differences in concentrations of prostatespecific antigen and prostate-specific antigen-a r antichymotrypsin complex in healthy subjects
The levels of prostate-specific antigen were, s to be expected, higher in healthy men than in healthy women (men-median 1.27 μg/l, women-median 0.16 μg/l, p < 0.01 Mann Whitney U-test). The levels of prostate-specific antigen-ai-antichymotrypsin complex were also higher in healthy men than in healthy women (men-median 1.18 μ §/1, women-median 0.78 μg/l), although this difference was not significant.
Patients with prostatic cancer and benign hyperplasia or hypertrophy of the prostate
Assays employing prostate-specific antigen and prostate-specific antigen-ot! -antichymotrypsin complex were compared for their ability to differentiate between benign and malignant prostate disease.
Twenty patients with clinically confirmed prostate carcinomata with (12/20) and without (8/20) metastasis were compared with 15 patients presenting with benign prostatic hypertrophy or hyperplasia (9/15) or prostatitis (6/15).
Whereas all carcinoma/adenoma patients h d pathologically elevated concentrations of prostate-specific antigen, normal prostate-specific antigen-oc r antichymotrypsin complex levels were seen in three cases of prostate carcinoma. In the benign prostatic hyperplasia group 6/9 presented with elevated prostate-specific antigen and 5/9 with elevated prostate-specific antigen-ai-antichymotrypsin complex. In the patients with prostatitis 4/6 presented with elevated prostatespecific antigen and 3/6 with elevated prostate-specific antigen-a^antichymotrypsin complex. The results are summarised in table 3a-3c. Patients with other urological disorders 30 male patients attending the urology cliriic for nephrolithiasis (n = 20) and urinary tr ct infections (n = 10) were taken s a control group. The r nge of prostate-specifie antigen concentrations was 0.27-4.21 μg/l (median 1.73 μg/l) and for prostate-specific antigen-arantichymotrypsin complex 0.16-2.87 μ^/1 (median 0.66 μg/l). The values correlated with each other in a simil r way t those frorh healthy iridividc-uals (r = 0.53, p < 0.005). Twp patients had elevated results, one in each assay.
. l 
Bacterial and viral infections -Effects on measured concentrations of prostate-specific anligen-v.rantichymotrypsin complex
There was a correlation between arantichymotrypsin levels and measured prostate-specific antigen-arantichymotrypsin complex levels in patients with bacterial and or viral infection, but without prostate disease, showing that high arantichymotrypsin levels may lead to an increase in measured prostate-specific antigen-arantichyrnotrypsin complex concentrations in such patients. Figure l shows the relationship between prostate-specific antigen, prostate-specific antigen-arantichymotrypsin complex and elevated a r antichymotrypsin based on 10 selected patients. The correlation between prostate-specific antigen and prostate-specific antigen-ai-antichymotrypsin complex is markedly better (r = 0.85 compared with r = 0.57) when patients with high arantichymotrypsin are excluded ( fig. 2 ).
Values of arantichymotrypsin above 2 g/l (more than 3 times the upper limit of the reference r nge described above) are likely to give rise to pathological values for prostate-specific antigen-α! -antichymotrypsin complex. This means that in patients with bacterial infections, care must be taken in interpreting prostatespecific antigen-ai-antichymotrypsin complex levels.
In patients with elevated prostate-specific antigen levels and normal or slightly elevated arantichymotrypsin the correlation between prostate-specific antigen and prostate-specific antigen-α! -antichymotrypsin complex is excellent. The slope of the regression line is not unity, due to the materials used for calibration. Purified prostate-specific antigen (M r 30 000) is used for calibrating the commercial kits, whereas naturallyoccurring prostate-specific antigen-arantichymotrypsin complexes (M r 100000) were prevalent in the serum used for calibrating the sandwich assay for prostate-specific antigen-arantichymotrypsin complex.
Extra wash Steps reduce carry-over considerably without significantly reducing the specific binding. In a study on 63 urological patients, without prostatic cancer and with normal and elevated arantichymotrypsin levels, all were assayed for prostate-specific antigen, s well s for prostate-specific antigen-a r antichymotrypsin complex with 2 χ 5 ml wash Steps (assay method 1) and 4 χ 5 ml wash Steps (assay method 2). The results are shown in Range of a r antichymotrypsin 0.22-2.01 g/l (median 0.52 g/l).
Assay method l -with 2 χ 5 ml wash Steps between incubations.
Range of prostate-specific antigen-ai-antichymotrypsin complex 0.14-2.87 g/l (median 0.68 g/l).
Assay method 2 -with 4 χ 5 ml wash Steps between incubations.
Range of prostate-specific antigen-ocraniichymotrypsin complex 0.08-1.64 g/l (median 0.44 μg/l).
Wilcoxon signed rank test assay method l vs assay method 2 p < 0.001.
Linear regression data prostate-specific antigen vs prostateŝ pecific antigen-ai-antichymotrypsin complex Assay method l -r (Spearman) 0.507 p < 0.005 Assay method 2 -r (Spearman) 0.483 p < 0.005 elevated αι-antichymotrypsin showed much reduced non-specific binding after increased washing (see figure 3 -selected sera) .
Prostate-specific antigen, prostate-specific antigen-a. r antichymotrypsin complex levels in other groups with non-prostatic disease
Four from 6 females with pulmonary infections had falsely elevated prostate-specific antigen-ai-antichymotrypsin complex due to interference from excessively high αι-antichymotrypsin concentrations in their serum. These four patients are number 7, 8, 9 and 10 in figurel.
Reports have been published of antibodies to prostate-specific antigen, which may give rise to measurable prostate-specific antigen concentrations in women (11) . In the present investigation, prostatespecific antigen levels were therefore also studied in sera from women, s part of a general study of "problem patients" (with regard to latioratory tests). A 46-year old woman was found to have "prostate-specific antigen-antibodies" which gave rise to elevated "prostate-specific antigen" levels in the prostate-specific antigen radioimmunoassay. In this case, a prostatespecific antigen value of 5.2 μg/l (prostate-specific antigen-ai-antichymotrypsin complex 0.20 μg/l) was measured. The serum had a high unspecific binding of labelled prostate-specific antigen after polyethylene glycol precipitation, which indicated the presence of antibodies to prostate-specific antigen. A similar case was seen in a 54 year old man with nephritis who had "prostate-specific antigen-levels" of 21.8 μg/l, prostate-specific antigen-ai-antichymotrypsin complex levels of 0.27 and αι-antichymotrypsin of 0.58 g/l.
Sera from a group of reiial insufficiency patients, s well s those with proven Jung carcinom , were also checked for "prostate-specific antigen" and "prostatespecific antigen-ai-antichymotrypsin complex".
In one case of renal insufficiency, a prostate-specific antigen level of 5.3 μg/l was measured. Prostate-specific antigen-ai-antichymotrypsin complex was normal (1.20 μg/l). A 90 year old man with a phimosis had elevated prostate-specific antigen (pre-op. 10.1 μg/l, post-op. 11.4 μg/l) s well s prostate-specific antigen-a r antichymotrypsin cojnplex (pre-op. 2.86 μg/l, post-op. 2.14 μg/l). in one case of prostatic cancer treated by bilateral orchidectomy, prostatespecific antigen levels were 0.27 μg/l and prostatespecific antigen-ai-antichymotrypsin complex 0.09 5 6 Patient No. Fig. 3 . Selected patients with normal serum prostate-specific antigen levels and with grossly elevated arantichymotrypsin (> 2 g/l) in serum. The effects on "prostate-specific antigen-oci-antschymotrypsin complex levels" by washing with 2 χ 5 ml and 4 χ 5 ml between incubation Steps are shown. »i μg/l six months after Operation. Nephrolithiasis patients (n = 20) and patients with urinary tract infections (n = 10) had normal levels of prostate-specific antigen, prostate-specific antigen-a r antichymotrypsin complex and arantichymotrypsin. One woman with lung cancer had elevated levels of prostate-specific antigen and prostate-specific antigen-arantichymotrypsin.
Discussion
Although the introduction of the assay for prostatespecific antigen has led to a better discrimination between patients with prostatic cancer and those with inflammation of the prostate, there is still some overlap between both groups, which reduces the clinical specificity and sensitivity of the test. As it has been shown that prostate-specific antigen normally circulates s a complex with ai-antichymotrypsin (8), an assay was developed to see whether the measurement of prostate-specific antigen-arantichymotrypsin complex would improve the diagnostic value of the prostate-specific antigen determination. This would be analogous to the measurement of elastase-oci-antitrypsin (10).
The results show that the assay for prostate-specific antigen-arantichymotrypsin complex is much quicker than that for prostate-specific antigen, s well s needing a smaller sample volume. Difficulties arise, however, due to non-specific adsorption of a r antichymotrypsin to the solid phase and to the production of prostate-specific antigen not coupled to a r antichymotrypsin, s seen in three patients with metastasis. Increasing the number of wash steps (4 χ 5 ml) between each incubation reduces the unspeciflc adsorption effects due to arantichymotrypsin, although it does not completely alleviate the problem. Although falsely elevated results do not become apparent until αι-antichymotrypsin levels exceed three times the upper limit of the reference r nge for healthy volunteers, such levels can occur in extreme cases of bacterial infection, s seen in cases of pulmonary sepsis (see fig. 1 ), where the female patients with "elevated prostate-specific antigen^arantichyinotrypsin complex" were all from the pulmonary unit.
The advantages of the prostate-specific antigen-a r antichymotrypsin complex assay are its short incubation times and its ability to give "correct answers" in the rare cases of patients with "anti-prostate-specific antigen-like activity" (11) .
As both Af r 30000 and M T 100000 "prostate-specific antigen" (free and complexed) have been seen in electrophoresis of seminal fluid (8), the ratio of prostatespecific antigen to prostate-specific antigen-arantichymotrypsin complex may be a useful clinical indicator, but this involves the performance of an additional laboratory test.
Purified prostate-specific antigen (M r 30000) (1) did not complex with a 3 -antichymotrypsin in plasma, showing either that the active formation of complexes normally takes place in the prostate, or that the prostate-specific antigen had lost its ability to combine with αι-antichymotrypsin during purification.
There were interesting cases where a woman with "prostate-specific antigen-like immunoreactivity" had an elevated unspecific binding of prostate-specific antigen tracer if the serum was precipitated with polyethylene glycol (end concentration 150 g/l), which pointed to the presence of antibodies to prostatespecific antigen. One man with nephritis also had antibodies to prostate-specific antigen. Three cases of metastasing prostate carcinoma had discrepant values for prostate-specific antigen and prostate-specific antigen-arantichymotrypsin complex (prostate-specific antigen 8.56, 30.0 and 107 μg/l, prostate-specific antigen-arantichymotrypsin complex 0.78, 3.72 and 1.24 μg/l) (Cases 10-12 -tab. 3a). The latter cases point to the production of an abnormal neoplastic prostate-specific antigen which was incapable of binding to arantichymotrypsin in the normal way, s a r antichymotrypsin was present in serum in normal concentrations.
To conclude, both assays can be used in the diagnosis and follow up of prostatic cancer, the results from the prostate-specific antigen-arantichymotrypsin complex assay being available on the same day, using a sample of only 110 μΐ for a duplicate determination. This is offset by the fact that grossly elevated levels of aj-antichymotrypsin may give rise to falsely elevated prostate-specific antigen-ai-antichymotrypsin complex levels in serum or plasma, which can be reduced but not fully excluded by increasing the number of wash Steps. Further experimentation is needed to examine whether the prostate-specific antigen-arantichymotrypsin complex assay can be used in post-op. followup and early diagnosis of metastases. Whether the ratio, free: complexed prostate-specific antigen, may act s an indicator of metastatic growth (supported by cases 10-12, tab. 3a) must also be investigated further.
In the light of the present results, prostate-specific antigen-a r antichymotrypsin complex alone is not expected to be more specific than prostate-specific antigen or prostate acid-phosphatase s a screening parameter.
